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Abstract
Background: The recent introduction of an entirely subcutaneous implantable cardioverter-defibril-
lator (S-ICD) represents an important progress in the defibrillation technology towards a less invasive 
approach. This is a single-center observational study of S-ICD implantations in Poland.
Methods: The S-ICD was implanted in 11 patients with standard indications for an ICD. Patients 
in whom the device was implanted were evaluated for adverse events and device function at hospital 
discharge. All  hospitalization costs were calculated and summed up for all patients. Costs were divided 
into following categories: medical materials, pharmaceuticals, operating theatre staff, cardiology depart-
ment staff, laboratory tests, non-laboratory tests and additional non-medical costs.
Results: The mean age of patients was 51.6 ± 16.4 years, 9 were men and 2 were women. Four pa-
tients had atrial fibrillation as the basal rhythm, 1 patient had atrial flutter and 6 patients had sinus 
rhythm. All patients had at least one condition that precluded the use of a traditional ICD system or 
the S-ICD was preferred due to other conditions, i.e. a history complicated transvenous ICD therapy 
(18%), anticipated higher risk of infection (27%), lack or difficult vascular access (18%), young age 
and anticipated high cumulated risk of lifetime device therapy (36%). The mean duration of the im-
plantation procedure was 2 h. One patient developed a postoperative pocket hematoma. Mean total time 
of hospitalization was 28 (6–92) days. Average cost of hospitalization per patient was 21,014.29 EUR 
(minimal = 19,332.71 EUR and maximal = 24,824.14 EUR). 
Conclusions: S-ICD implantation appears to provide a viable alternative to transvenous ICD, espe-
cially for patients without pacing requirements. (Cardiol J 2019; 26, 4: 360–367)
Key words: leadless, primary prevention, procedure cost, secondary prevention,  
subcutaneous implantable cardioverter-defibrillator, ventricular arrhythmias
Introduction
Sudden cardiac death (SCD) continues to be 
a major public health challenge, representing close 
to one-fifth of all mortality in industrialized coun-
tries and claiming about half of its victims not pre-
viously diagnosed with heart disease [1]. In recent 
decades implantable cardioverter-defibrillators 
(ICDs) have become the treatment of choice in 
patients with a high risk of fatal ventricular ar-
rhythmia [2]. A weak component of traditionally 
used ICD systems is the defibrillation lead, which is 
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placed through the venous circulatory system into 
the right ventricle. It was shown that the longevity 
of defibrillation leads have become substantially 
reduced, and risk of infection is significantly higher 
compared to pacing leads [3]. The subcutaneous 
implantable cardioverter-defibrillator (S-ICD) was 
developed in response to endovascular lead com-
plications and represents important progress in de-
fibrillation technology. After obtaining Conformité 
Européene (CE) marking in 2009 and United States 
(US) Food and Drug Administration (FDA) approval 
in 2012, there is growing clinical evidence regard-
ing its safety and efficacy in prevention of SCD 
[4–11]. This novel technology seems promising and 
particularly beneficial in patients with conditions 
associated with higher risk of infections (dialysis, 
diabetes mellitus) or in those who had experienced 
previous complications related to transvenous (TV) 
leads. The clinical benefits of S-ICD therapy have 
been also documented in young patients facing 
a lifetime of device therapy [12, 13]. 
The availability of S-ICD therapy is limited 
in Poland due to a lack of reimbursement and the 
cost of the device itself is around 7-times higher 
than conventional transvenous single chamber 
ICD. Further advancements of this system and 
cost reduction will likely lead to the expansion of 
indications and widespread use of this technology. 
An analysis of the indications was performed, 
procedural data and the full costs of hospitaliza-
tion of patients implanted with the S-ICD in single 
Polish center.
Methods
Procedure
The first four implantations were performed 
with the aid of three different international proc-
tors who had sufficient experience in the proce-
dure. Subsequent S-ICD implant surgeries were 
performed by two operators from Department of 
Cardiology of Central Teaching Hospital, Warsaw, 
Poland. All procedures were performed under 
general anesthesia. In nine cases, the pocket for 
the generator was created between the serratus 
anterior and the latissimus dorsi muscles. In the 
other 2 cases (case 2 and 3) subcutaneous device 
placement were used based on proctor advice. The 
lead was positioned in the subcutaneous tissue of 
the chest, parallel to and 1–2 cm to the left sternal 
midline followed by a perpendicular segment, at the 
level of the 6th rib, until it reached the pocket of the 
device. The lead had a 8-cm shock coil, flanked by 
two sensing electrodes — the distal one positioned 
close to the manubriosternal joint and the proximal 
one adjacent to the xiphoid process based on pre-
procedural X-ray imaging. Immediately after implan-
tation, the most suitable sensing vector (primary, 
secondary or alternate) was chosen automatically 
by the S-ICD. The detection was set for two zones 
(a conditional shock zone and shock zone depending 
on the patient’s indication and condition). Duration 
of procedure as total implantation time (time from 
patient in to patient out) and in-hospital adverse 
events related to the procedure were evaluated. 
Patients
None of the patients had absolute indication for 
permanent pacing. Prior to the procedure patients 
were screened with a manual screening tool to 
assess the applicability of this technology. All the 
patients were informed of the characteristics of the 
new system, indications and potential complica-
tions. Informed consents were obtained.
Costs of hospitalization analysis
All costs of hospitalization were calculated and 
summed up for all patients. Costs were divided 
into following categories: S-ICD hardware (a de-
vice plus a defibrillation lead), medical materials 
excluding S-ICD (disposable materials related 
to the procedure, lead introducer), pharmaceu-
ticals (oral drugs, antibiotics, disinfectants, anal-
gesics), operating theatre staff (electrophysiolo-
gists, scrub nurse, personal costs of analgesia), 
cardiology department staff (cardiologists, nurses), 
additional laboratory tests, additional non-labora-
tory tests (echocardiography, X-ray), additional 
non-medical costs (materials and energy, linen, 
maintenance materials, office supplies, informatics 
and information technology, laboratory reagents, 
medical gases, electricity, heat, water, permanent 
foreign services, postage and telephone charges 
— non-medical indirect costs, management). 
Costs are in euro currency, using then current 
exchange rate (2017-10-06): 1 euro (EUR) = 4.24 
Polish zloty (PLN).
Results
The S-ICD implantation was attempted in 
11 patients with 100% success rate. All the patients 
had standard indications for ICD implantation that 
can be divided into two broad categories: second-
ary (45.5% of patients) and primary prophylaxis. 
For secondary prophylaxis, ICD placement was 
indicated as initial therapy in survivors of sudden 
cardiac arrest due to ventricular fibrillation (VF) 
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or hemodynamically unstable ventricular tachycar-
dia (VT). For primary prophylaxis ICD placement 
was indicated as therapy in patients with low left 
ventricular ejection fraction (LVEF) ≤ 35% related 
do prior myocardial infraction or structural heart 
disease.
The mean age of the patients was 51.6 ± 16.4 
years, 9 were men. Four patients had atrial fibril-
lation (AF) as the basal rhythm, 1 patient — atrial 
flutter (AFI) and 6 patients — sinus rhythm. One 
patient had previously implanted cardiac resyn-
chronization therapy (CRT), that was removed 
during the hospitalization due to infective endo-
carditis. All patients had at least one condition that 
precluded the use of a traditional ICD system or 
had the condition that made the S-ICD more prefer-
able, i.e. a history of previous complicated TV-ICD 
(18%), anticipated higher risk of infection (27%), 
lack or difficult vascular access (18%), young age 
and anticipated high cumulated risk of lifetime 
device therapy (36%). Patient characteristics and 
basic procedural data are summarized in Table 1.
The mean duration of the implantation proce-
dure was 2 h. One patient developed a postopera-
tive pocket hematoma treated conservatively. The 
same patient experienced severe gastrointestinal 
bleeding not directly associated with the procedure 
but related to oral anticoagulant treatment. The 
complication was treated with endoscopy accom-
panied with blood transfusion (8 units of packed 
red blood cells). Mean total time of hospitalization 
was 28 (6–92) days. The time from admission to 
the procedure ranged from 1 to 81 days (mean 18 
days) and from procedure to discharge from 4 to 
27 days (mean 10 days). 
During follow-up (mean time 17.5 ± 9.6 
months) all patients survived. There was no nei-
ther infection nor a need for battery replacement 
but 1 patient needed re-intervention due to in 
pocket device dislocation (case 3 with subcutane-
ous device placement). In 3 patients at least one 
appropriate therapy occurred and 1 patient had an 
episode of inappropriate therapies due to myopo-
tentials.
The real costs of hospitalization for every pa-
tient are presented in Table 1. Average cost of hos-
pitalization per patient was 21,014.29 EUR (mini-
mal = 19,332.71 EUR and maximal = 24,824.14 
EUR). Average costs for each category were as 
follows: 18,548.84 EUR for S-ICD, 142.66 EUR for 
medical materials excluding S-ICD; 142.87 EUR for 
pharmaceuticals; 157.14 EUR for operating theatre 
staff; 871.93 EUR for cardiology department staff; 
399.33 EUR for laboratory additional tests, 221.13 
EUR for non-laboratory additional tests; 521.65 
EUR for additional non-medical costs.
Discussion
The S-ICD has recently entered into the clini-
cal practice and represents a valid alternative for 
patients who have indications for ICD implanta-
tion, especially for those, whose clinical condition 
makes the risk of traditional TV-ICD implantation 
notably high. It becomes a less invasive option for 
patients in whom TV-ICD implantation is surgi-
cally impossible. It is estimated that up to 55% of 
patients in routine clinical practice needing an ICD 
are potential candidates for a subcutaneous device 
[14, 15]. However, to maximize clinical outcome 
and cost/benefit ratio, it is fundamental to choose 
candidates that can benefit most, taking into ac-
count both patient and device characteristics. 
Based on recently released (2015) Clinical 
Practice Guidelines for the Prevention of Sudden 
Cardiac Death of the European Society of Cardi-
ology (ESC), the use of the S-ICD system may 
be useful, alternatively to the TV-ICD system, 
when venous access is difficult (especially due to 
congenital anomalies — writer’s note), in young 
patients facing a lifetime of device therapy and in 
patients after the removal of a TV-ICD system for 
infection (Class IIb-C) [2]. Moreover, the device 
is recommended as an alternative to TV-ICDs 
when pacing therapy for bradycardia, cardiac re-
synchronization or antitachycardia pacing is not 
needed (Class IIa-C) [2]. In recent 2017 AHA/ 
/ACC/HRS Guideline for Management of Patients 
with Ventricular Arrhythmias and the Prevention 
of SCD the use of S-ICD has become a Class I-B 
indication for the mentioned patient group [16]. 
Because the risk of infection appears to be lower, 
S-ICD may be preferred in patients who are at high 
risk of infection, such as those with a prior device 
infection, end-stage renal failure, diabetes mellitus, 
or those who are chronically immunosuppressed. 
This means that majority of ICD indicated patients 
(without pacing needs) should be considered for S-
ICD according to Class IIa indication endorsed by 
recent guidelines [17]. Although according to above 
mentioned recommendations S-ICD can be used in 
most ICD candidates, due to cost issues in Poland 
it is possible to introduce this novel therapy only in 
very selected group of patients. This was reflected 
in the characteristics of the present study popula-
tion and may be comparable to recently published 
data from a European survey showing the following 
main reasons favoring the use of an S-ICD: young 
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age, lead-related complications, elevated risk or 
previous device infection, and also patient pref-
erence or active lifestyle [18]. In our population 
2 patients with the history of cardiac device-related 
infective endocarditis (CDRIE), the S-ICD was 
implanted due to increased risk of infection related 
to the necessity of device re-implantation as well as 
increased levels of inflammatory parameters during 
the entire period of hospitalization. Additional risk 
factors for those patients were: advanced diabetes 
mellitus complicated by diabetic food syndrome in 
1 patient and composite of CAD and heart valvular 
disease in the second one. 
In 2 patients, TV-ICD implantation was pro-
hibited by venous system anatomy, that made 
placement of a lead difficult or even impossible or 
the lack of vascular access associated with the need 
of intravenous nutrition. Recent studies show that 
venous abnormalities are not rare among patients 
requiring pacemaker or ICD therapy and pres-
ence of stenosis or obstruction of central veins (in 
absence of congenital anomalies) can be found in 
up to 7% of cases during pre-implant intravenous 
contrast venography [19], thus further develop-
ment of this technology can make it first line option 
in these situations.
Finally, in 4 patients, S-ICD was chosen in-
stead of TV-ICD due to long life expectancy. In 
those cases, implanting a TV-ICD with an endocar-
dial lead system could put the patient at increased 
risk of serious systemic and potentially mortal 
complications such as CDRIE. Here it is worth 
mentioning that new reports confirmed safety and 
effectiveness of this system in children [20, 21] 
though implantation in patients with low body mass 
index should be carefully considered due to the 
relatively large and heavy generator. Channelopa-
thies, hypertrophic cardiomyopathy (HCM), dilated 
cardiomyopathy (DCM), are very common prob-
lems among young people [22], which is in accord 
with this study, and those in whom the mechanism 
of SCD usually involves polymorphic VT or VF, and 
those with low risk of bradycardia and monomor-
phic VT requiring Anti Tachycardia Pacing (ATP) 
theoretically constitutes a group where S-ICD may 
be the preferable option. However, it should be 
noted that a higher rate of inappropriate shocks due 
to T-wave oversensing and double-counting has 
been recorded in these patients [23, 24]. For exam-
ple, in patients with Brugada syndrome, although 
clinical efficacy of S-ICD has been demonstrated, 
the more recent experience in Europe suggests 
that S-ICD screening failure occurs in up to 13% 
of those patients [24]. Rate of inappropriate S-ICD Ta
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shocks ranges between 4% and 15%, [23, 25–27] 
that is not so different from TV-ICD [7, 24], but 
with a different mechanism: up to 80% is caused 
by T-wave oversensing (TWOS), especially in some 
patient populations (i.e. congenital heart disease, 
Brugada and long QT syndromes), while in TV-ICD 
TWOS is involved in about 20% of cases [4, 5, 25, 
26]. This aspect is important because it underlies 
the importance of exercise testing shortly after 
the implantation, as well as adopting a detailed 
patient screening practice with selection of the 
optimal sensing vector in different positions to 
reduce the risk of TWOS [28, 29]. Careful screen-
ing, software updates and template selection has 
reduced the occurrence of inappropriate shocks 
with the current S-ICDs when compared with the 
earlier experiences [29]. 
Another concern that has been raised is that 
there was no pacing capability (with the exception 
of 30” post-shock backup pacing) within S-ICD 
therapy which also means no possibility to deliver 
ATP for management of refractory monomorphic 
VT. This aspect was crucial in deciding on S-ICD 
implantation in the last patient in whom the ben-
efits of S-ICD implantation (central venous cir-
culation protection, avoidance of the lead related 
complications etc.) outweighed the lack of ATP 
function. The SCD-HeFT study showed that after 
almost 3 years of follow-up, only a third of patients 
with VT had more than one episode, which trans-
lated to 1.8% annual risk [30, 31]. In one cohort of 
patients it was shown that 55.5% (95% confidence 
interval 52.0–59.0%) of single or dual chamber 
ICDs recipients did not require pacing or receive 
ATP after 5 years and therefore could have been 
eligible to receive an S-ICD instead. The Pac-
ing Fast Ventricular Tachycardia Reduces Shock 
Therapies (Pain-FREE Rx II) trial [32] showed that 
patients randomized to receive shock-only, 34% of 
fast VT episodes terminated spontaneously before 
therapy, suggesting that a considerable proportion 
of ATP intervention, which is delivered before 
a shock, may be unnecessary. Furthermore, ATP is 
not without risk; it is possible for ATP to accelerate 
VT to polymorphic VT or VF [33–35] which has 
been associated with a higher mortality risk [36]. 
In conclusion, the lack of ATP function in the S-ICD 
is a contentious one [37].
According to the latest reports of the current 
use of S-ICDs across a broad range of European 
centers, the most reported reasons for preferring 
an S-ICD over implantation of a TV-ICD are: an 
anticipated difficult vascular access (82% of the 
centers), a history of previous complicated TV-ICD 
(80% of the centers), young age (69%), an antici-
pated higher risk of infection (63%), the availability 
of the new generation S-ICD (53% of the centers), 
or a primary prevention indication (45% of the cent-
ers) [10]. In the present study the most common 
indication for S-ICD implantation was the young 
age of patients facing a lifetime of device therapy 
thus avoiding the lead-related complications (40% 
of patients), what can be explained by new reports 
demonstrated that lead failure rates are higher in 
younger patients [25, 38].
In the aforementioned study, more than one-
fourth (n = 14, 27%) of the respondents have never 
implanted an S-ICD. The main reasons reported by 
these centers for the non-use of S-ICD include eco-
nomic issues, such as lack of reimbursement (25% 
were not implanting centers), high cost of the device 
(25% of centers) and less often claimed issues were 
the lack of training (19% of centers), the complexity 
of the implantation procedure (6% of centers) [10]. 
Those results also reflect limitations in S-ICD im-
plantation, that started in the documented hospital 
from 2015 [39]. Although implantation of TV-ICD is 
on the list of guaranteed services, total cost of S-ICD 
highly exceeds reimbursement level for this catego-
ry, so individual financing was implemented for each 
patient and this paper depicts expenditures divided 
into range of categories. In the Honarbakhsh et al. 
[40] study, comparing efficacy, safety and costs of the 
S-ICD vs. TV-ICD, even though more expensive, 
S-ICD was associated with a relative risk reduction 
of device-related complication of 70% with a hazard 
risk of 0.30 (95% confidence interval 0.12–0.76; 
p = 0.01) compared to TV-ICDs. The total mean cost 
for each group, including the complication-related 
costs was £9967 ± 4511 ($13,639 ± 6173) and 
£12,601 ± 1786 ($17,243 ± 2444) in the TV-ICD 
and S-ICD groups respectively (p = 0.0001) [19]. It 
shows that despite the existing significant difference 
in unit cost of the S-ICD, overall S-ICD costs may 
be mitigated versus TV-ICDs over a longer follow-
up period. If the incidence rate of TV-ICD-related 
complications [40] remains stable over the next years 
no cost difference between these two groups would 
be expected.
Until now, there is still relatively little data 
regarding long term performance of the S-ICD in 
a “real world” setting so larger experience and 
longer follow up are required, but initial results 
are encouraging [41, 42].
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Limitations of the study
This single center experience was not rand-
omized and shows the short term, initial experi-
ence of the present small group of patients. This 
implies that no real data on long-term performance 
of the device and its longevity were available. 
A low number of patients in the present cohort is the 
main limitation of the above analysis. However, the 
aim of the analysis was to present the initial expe-
rience of the operating team with the new treat-
ment method in a single center and to present full 
hospitalization costs of “real-world” consecutive 
patients. Such data might be valuable for regional 
authorities to support decisions on reimbursement 
and for appropriate valuations of the procedure.
Conclusions
Current evidence suggests that S-ICD is 
a highly effective and safe modality with comparable 
defibrillation success rate to conventional ICDs. 
Thus, a wide range of patients without pacing re-
quirements, and particularly younger patients, may 
benefit. Ongoing clinical studies will help establish 
the S-ICD system long-term safety and efficacy and 
better define target patient groups.
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